Last checked at 24 Jun 2020 09:54
Director Dealings / Market Share Disposal - Replacement
This announcement replaces an earlier version (RNS 8552Q) correcting "Purchase" in the title to "Disposal". All other details remain unchanged and the full text is shown below.
Oxford, UK - 24 June 2020: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo Fund and Vulpes Life Sciences Fund, persons closely associated with Martin Diggle, Non-Executive Director, has disposed of 89,434 and 134,149 ordinary shares of 50p each ("Ordinary Shares") in the Company on 22 June 2020 on the London Stock Exchange at a price of 807.8p and 807.8p per share. Following these disposals Vulpes Testudo/Vulpes Life Sciences Fund holds 11,452,435 ordinary shares representing 14.0% of the Company.
The Vulpes Testudo/Vulpes Life Sciences Fund has several investments across the life sciences sector of which the shareholdings in Oxford Biomedica have become increasingly significant as a proportion of the overall funds under management. The proceeds from this sale are expected to be invested in other portfolio companies in the near future.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | 1. Vulpes Testudo Fund 2. Vulpes Life Sciences Fund
| |
2. | Reason for the notification
| ||
a. | Position/status | 1. Person closely associated with Martin Diggle, Non-Executive Director 2. Person closely associated with Martin Diggle, Non-Executive Director | |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford Biomedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Oxford Biomedica plc Ordinary Shares of 50p each
GB00BDFBVT43
| |
b. | Nature of the transaction | Disposal of ordinary shares
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
1. £8.08 2. £8.08 | 1. 89,434 2. 134,149
| ||
|
| ||
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
N/A
| |
f. | Date of the transaction | 2020-06-22
| |
g. | Place of the transaction | London Stock Exchange, Main Market (XLON)
| |
The issued share capital of the Group is 82,002,369 ordinary 50p shares.
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at www.oxb.com.